Pharmacokinetics and Safety of Fixed‐Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects

ABSTRACT Envlo (enavogliflozin) 0.3 mg, an SGLT2 inhibitor, was approved in Korea in 2022 for glycemic control in type 2 diabetes (T2DM). This study evaluates its safety, pharmacokinetics, and food effects. Healthy subjects (age ≥ 19, weight ≥ 50.0 kg, body mass index (BMI) 18.0–30.0 kg/m2) were enr...

Full description

Bibliographic Details

Published in:	Clinical and Translational Science
Main Authors:	Young‐Sim Choi, JAEJIN NA, Seo Yeong Park, Jae Min Cho, Yoonhye Jeong, Jun Gi Hwang
Format:	Article
Language:	English
Published:	Wiley 2025-10-01
Subjects:	enavogliflozin pharmacokinetics safety SGLT2 inhibitor type 2 diabetes mellitus
Online Access:	https://doi.org/10.1111/cts.70376